ArticleJAMA oncology2018
Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply.
Vinay Prasad et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it